News

President Donald Trump's tax cut and spending bill faces a critical stress test on Wednesday as Republicans in the U.S. House ...
Novavax shares surged more than 17% before the bell on Monday, following the long-delayed approval of its COVID-19 vaccine ...
Novavax can finally breathe a sigh of relief – at least a small one. The Food and Drug Administration approved the company's ...
The U.S. Food and Drug Administration approved Novavax's COVIDd-19 vaccine with age restrictions after a six-week delay.
The agency narrowed who can get the shot and added new study requirements that could cost the company tens of millions.
After a six-week delay, the US Food and Drug Administration has approved Novavax’s Covid-19 vaccine, according to a letter ...
In its Friday approval letter, the FDA didn’t explain the restrictions although they reflect skepticism about ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years ...
The Food and Drug Administration says it has decided to continue approving COVID-19 vaccine updates for seniors and others at ...
Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at ...
While the clearance is only for use in certain groups, Novavax’s long-awaited OK is still seen by analysts as a “win” for the ...
At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...